Negative metabolic and coronary flow effects of decreases in cAMP and increases in cGMP in control and renal hypertensive rabbit hearts

Journal of Applied Physiology

Volumn 97, Issue 1, 2004, Pages 439-445

  Rodriguez, Roberto ^a   Molino, Bruno ^a   Weiss, Harvey R ^a   Scholz, Peter M ^a,b  

^a RUTGERS ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^b ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

Author keywords

Coronary blood flow; Hypertension; Myocardial oxygen consumption; Second messengers

Indexed keywords

8 BROMO CYCLIC GMP; CYCLIC AMP; CYCLIC GMP; PROPRANOLOL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; ENDOCARDIUM; EPICARDIUM; HYPERTENSION; METABOLISM; NONHUMAN; OXYGEN CONSUMPTION; PRIORITY JOURNAL; RABBIT; RENOVASCULAR HYPERTENSION; SPECTROPHOTOMETER;

ADRENERGIC BETA-ANTAGONISTS; ANIMALS; BLOOD GAS ANALYSIS; BLOOD PRESSURE; CARDIAC OUTPUT; CORONARY CIRCULATION; CYCLIC AMP; CYCLIC GMP; HEART; HEART RATE; HYPERTENSION, RENOVASCULAR; KIDNEY; MYOCARDIUM; ORGAN SIZE; OXYGEN CONSUMPTION; PROPRANOLOL; RABBITS; SECOND MESSENGER SYSTEMS;

EID: 3042558479     PISSN: 87507587     EISSN: None     Source Type: Journal    
DOI: 10.1152/japplphysiol.01115.2003     Document Type: Article

References (31)

1. Campese VM and Krol E. Neurogenic factors in renal hypertension. Curr Hypertens Rep 4: 256-260, 2002.
2. Chiu WC, Kedem J, Weiss HR, Tse J, Cheinberg BV, and Scholz PM. Milrinone, a cyclic AMP-phosphodiesterase inhibitor, has differential effects on regional myocardial work and oxygen consumption in experimental left ventricular hypertrophy. Cardiovasc Res 28: 1360-1365, 1994.
3. Chowdhary S and Townsend JN. Nitric oxide and hypertension: not just an endothelium derived relaxing factor! J Hum Hypertens 15: 219-227, 2001.
4. Cimini CM, Gonzalez MA, and Weiss HR. Reduction of cardiac hypertrophy in renal hypertensive rabbits with pindolol. J Pharmacol Exp Ther 257: 541-546, 1991.
5. 2+ channels by cyclic AMP and cyclic GMP-dependent protein kinase in Pleurodeles oocytes. Mol Cell Biochem 168: 155-161, 1997.
6. Guo X, Kedem J, Weiss HR, Tse J, Roitstein A, and Scholz PM. Effect of cyclic GMP reduction on regional myocardial mechanics and metabolism in experimental left ventricular hypertrophy. J Cardiovasc Pharmacol 27: 392-400, 1996.
7. Hanes DS and Weir MR. The beta blockers: are they as protective in hypertension as in other cardiovascular conditions? J Clin Hypertens (Greenwich) 3: 236-243, 2001.
8. Hove-Madsen L, Mery PF, Jurevicius J, Skeberdis AV, and Fischmeister R. Regulation of myocardial calcium channels by cyclic AMP metabolism. Basic Res Cardiol 91, Suppl 2: 1-8, 1996.
9. Huang MW, Scholz PM, and Weiss HR. Increases in myocardial cyclic GMP attenuate contractile delay in myocardial stunning. Can J Physiol Pharmacol 80: 804-810, 2002.
10. Joe EK, Schussheim AE, Longrois D, Maki T, Kelly RA, Smith TW, and Balligand JL. Regulation of cardiac myocyte contractile function by inducible nitric oxide synthase (iNOS): mechanisms of contractile depression by nitric oxide. J Mol Cell Cardiol 30: 303-315, 1998.
11. Laragh JH. Renovascular hypertension: a paradigm for all hypertension. J Hypertens 4, Suppl 4: S79-S88, 1986,
12. Leone RJ Jr, Weiss HR, and Scholz PM. Positive functional effects of milrinone and methylene blue are not additive in control and hypertrophic canine hearts. J Surg Res 77: 23-28, 1998.
13. Lincoln TM, Komalavilas P, and Cornwell TL. Pleiotropic regulation of vascular smooth muscle tone by cyclic GMP-dependent protein kinase. Hspertension 23: 1141-1147, 1994.
14. Lohmann SM, Fischmeister R, and Walter U. Signal transduction by cGMP in heart. Basic Res Cardiol 86: 503-514, 1991.
15. Movsesian MA. Beta-adrenergic receptor agonists and cyclic nucleotide phosphodiesterase inhibitors: shifting the focus from inotropy to cyclic adenosine monophosphate. J Am Coll Cardiol 34: 3-324, 1999.
16. Patel KN, Yan L, Gandhi A, Scholz PM, and Weiss HR. Interaction between the opposing functional effects of cyclic AMP and cyclic GMP in hypertrophic cardiac myocytes. Basic Res Cardiol 96: 34-41, 2001.
17. Paulus WJ, Vantrimpont PJ, and Shah AM. Acute effects of nitric oxide on left ventricular relaxation and diastolic distensibility in humans. Assessment of bicoronary sodium nitroprusside infusion. Circulation 89: 2070-2078, 1994.
18. Petrashevskaya NN, Koch SE, Bodi I, and Schwartz A. Calcium cycling, historic overview and perspectives. Role for autonomic nervous system regulation. J Mol Cell Cardiol 34: 885-896, 2002.
19. Prichard BN, Cruichshank JM, and Graham BR. Beta-adrenergic blocking drugs in the treatment of hypertension. Blood Press 10: 366-386, 2001.
20. Rabindranauth P, Naim KL, Scholz PM, Tse J, Sadoff JD, and Weiss HR. Negative metabolic effects of cyclic GMP are altered in renal hypertension induced cardiac hypertrophy. Basic Res Cardiol 92: 8-16, 1997.
21. Sabbah HN. The cellular and physiologic effects of beta blockers in heart failure. Clin Cardiol 22, Suppl 5: 16-20, 1999.
22. 2 consumption in control but not renal hypertension-induced cardiac hypertrophy. Cardiovasc Res 36: 435-459, 1997.
23. Shah AM and MacCarthy PA. Paracrine and autocrine effects of nitric oxide on myocardial function. Pharmacol Ther 86: 49-86, 2000.
24. 2+ in intact cardiac myocytes. Circ Res 74: 970-978, 1994.
25. Sperelakis N, Tohse N, Ohya Y, and Masuda H. Cyclic GMP regulation of calcium slow channels in cardiac muscle and vascular smooth muscle cells. Adv Pharmacol 26: 217-252, 1994.
26. Steinberg SF and Brunton LL. Compartmentation of G-protein-coupled signaling pathways in cardiac myocytes. Annu Rev Pharmacol Toxicol 41: 751-773, 2001.
27. 2 consumption is altered in renal hypertension. Am J Physiol Heart Circ Physiol 273: H1949-H1955, 1997.
28. Trochu JN, Bouhour JB, Kaley G, and Hintze TH. Role of endothelium-derived nitric oxide in the regulation of cardiac oxygen metabolism: implications in health and disease. Circ Res 87: 1108-1117, 2000.
29. Weiss HR, Gong GX, Straznicka M, Yan L, Tse J, and Scholz PM. Cyclic GMP and cyclic AMP induced changes in control and hypertrophic cardiac myocyte function interact through cyclic GMP affected cyclic AMP phosphodiesterases. Can J Physiol Pharmacol 77: 422-431, 1999.
30. 2 supply and consumption of rabbit hearts. Clin Exp Pharmacol Physiol 21: 607-614, 1994.
31. Zhu NH and Weiss HR. Oxy- and carboxyhemoglobin saturation determination in frozen small vessels. Am J Physiol Heart Circ Physiol 260: H626-H631, 1991.